Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity
2023 · EBioMedicine · 25 citations
https://doi.org/10.1016/j.ebiom.2023.104663
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
48
Papers
3.2K
Citations
19
h-index
21
i10-index
Maarten L. Janmaat is an academic researcher. The author has contributed to research in topics: Monoclonal and Polyclonal Antibodies Research & Phagocytosis and Immune Regulation & Cancer Immunotherapy and Biomarkers. The author has an h-index of 19, co-authored 41 publications.
ORCID: 0000-0003-4980-730XClick to start Chat